Results of ASCT in progressing/relapsing FL
| Author . | No. of patients . | Histological transformation, % . | Source of stem cells . | Conditioning regimen . | Purging . | Median follow-up, mo . | DFS . | OS . |
|---|---|---|---|---|---|---|---|---|
| Berglund et al3 | 22 | 50 | BM | BEAC +/− TBI | No | 74 | 72% at 74 mo | 81% at 74 mo |
| Voso et al4 | 41 | 0 | PB | CY-TBI (8 BEAM) | CD34+ selection | 44 | 43% at 44 mo | 72% at 44 mo |
| Apostolidis et al5 | 99 | 0 | BM | CY-TBI | Anti-B MoAbs + C′ | 66 | 63% at 66 mo | 69% at 66 mo |
| Freedman et al6 | 153 | 0 | BM | CY-TBI | Anti-B MoAbs + C′ | 96 | 42% at 96 mo | 66% at 96 mo |
| Weaver et al7 | 40 | 0 | PB | BU-CY or BEAC | No | 43 | 35% at 43 mo | 55% at 43 mo |
| Brice et al8 | 83 | 29 | PB 73% BM 27% | TBI 71% BEAM 29% | CD34 (22%) | 44 | 42% at 60 mo | 58% at 60 mo |
| Verdonck et al9 10 | 18 | 0 | BM | CY + TBI | No | 36 | 22% at 24 mo | 33% at 36 mo |
| Bastion et al11 | 48 | 14 | PB | CY + TBI | No | 21 | 53% at 21 mo | 76% at 21 mo |
| Colombat et al12 | 42 | 0 | BM 88% PB 12% | CY + TBI or BEAM | BM (40%) | 43 | 58% at 43 mo | 83% at 43 mo |
| Bierman et al13 | 100 | 0 | BM 13% PB 87% | CY + TBI or BEAM | No | 31 | 44% at 48 mo | 65% at 48 mo |
| Molina et al14 | 58 | 18 | PB | CY + TBI ± VP16 (or BCNU) | No | 62 | 42% at 60 mo | 67% at 60 mo |
| Cao et al15 | 49 | 0 | BM 38% PB 68% | CY + TBI + VP16 77% CY + BCNU + VP16 23% | Anti-B MoAbs if BM | 66 | 44% at 48 mo | 60% at 48 mo |
| Seyfarth et al16 | 22 | 0 | PB | CY + TBI 58% BEAM 16%; BU-CY 25% | CD34 (95%) | 48 | 38% at 48 mo | 73% at 48 mo |
| Cervantes et al20 | 34 | 0 PB | BM 70% PB 27% Both 3% | CY + TBI 91% BEAM 9% | Anti-B MoAbs + C′ | 40 | 18% at 24 mo | 35% at 60 mo |
| Author . | No. of patients . | Histological transformation, % . | Source of stem cells . | Conditioning regimen . | Purging . | Median follow-up, mo . | DFS . | OS . |
|---|---|---|---|---|---|---|---|---|
| Berglund et al3 | 22 | 50 | BM | BEAC +/− TBI | No | 74 | 72% at 74 mo | 81% at 74 mo |
| Voso et al4 | 41 | 0 | PB | CY-TBI (8 BEAM) | CD34+ selection | 44 | 43% at 44 mo | 72% at 44 mo |
| Apostolidis et al5 | 99 | 0 | BM | CY-TBI | Anti-B MoAbs + C′ | 66 | 63% at 66 mo | 69% at 66 mo |
| Freedman et al6 | 153 | 0 | BM | CY-TBI | Anti-B MoAbs + C′ | 96 | 42% at 96 mo | 66% at 96 mo |
| Weaver et al7 | 40 | 0 | PB | BU-CY or BEAC | No | 43 | 35% at 43 mo | 55% at 43 mo |
| Brice et al8 | 83 | 29 | PB 73% BM 27% | TBI 71% BEAM 29% | CD34 (22%) | 44 | 42% at 60 mo | 58% at 60 mo |
| Verdonck et al9 10 | 18 | 0 | BM | CY + TBI | No | 36 | 22% at 24 mo | 33% at 36 mo |
| Bastion et al11 | 48 | 14 | PB | CY + TBI | No | 21 | 53% at 21 mo | 76% at 21 mo |
| Colombat et al12 | 42 | 0 | BM 88% PB 12% | CY + TBI or BEAM | BM (40%) | 43 | 58% at 43 mo | 83% at 43 mo |
| Bierman et al13 | 100 | 0 | BM 13% PB 87% | CY + TBI or BEAM | No | 31 | 44% at 48 mo | 65% at 48 mo |
| Molina et al14 | 58 | 18 | PB | CY + TBI ± VP16 (or BCNU) | No | 62 | 42% at 60 mo | 67% at 60 mo |
| Cao et al15 | 49 | 0 | BM 38% PB 68% | CY + TBI + VP16 77% CY + BCNU + VP16 23% | Anti-B MoAbs if BM | 66 | 44% at 48 mo | 60% at 48 mo |
| Seyfarth et al16 | 22 | 0 | PB | CY + TBI 58% BEAM 16%; BU-CY 25% | CD34 (95%) | 48 | 38% at 48 mo | 73% at 48 mo |
| Cervantes et al20 | 34 | 0 PB | BM 70% PB 27% Both 3% | CY + TBI 91% BEAM 9% | Anti-B MoAbs + C′ | 40 | 18% at 24 mo | 35% at 60 mo |
Only series with at least 20 patients and reported as a full paper have been included. Registry data have not been included.
BM indicates bone marrow; PB, peripheral blood; CY, cyclophosphamide; TBI, total body irradiation; DFS, disease-free survival from HDT; OS, overall survival from HDT; BEAM, BCNU-etoposide-aracytine-melphalan; and BEAC, BCNU-etoposide-cyclophosphamide-aracytine.